{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T09:26:10Z","timestamp":1793179570140,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.mcna.2025.04.003","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:27:48Z","timestamp":1747898868000},"page":"1219-1239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Heart Failure Pharmacotherapy"],"prefix":"10.1016","volume":"109","author":[{"given":"Dusty L.","family":"Lisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Gaddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud H.","family":"Abdou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mcna.2025.04.003_bib1","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American Heart Association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2025.04.003_bib2","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/jac5.1450","article-title":"Pharmacist-led optimization of heart failure medications: a systematic review","volume":"4","author":"Cao","year":"2021","journal-title":"J Am Coll Clin Pharm"},{"key":"10.1016\/j.mcna.2025.04.003_bib3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction","volume":"77","author":"Maddox","year":"2021","journal-title":"JACC (J Am Coll Cardiol)"},{"issue":"17","key":"10.1016\/j.mcna.2025.04.003_bib4","first-page":"e264","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.mcna.2025.04.003_bib5","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.mcna.2025.04.003_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.cardfail.2017.04.014","volume":"23","author":"Yancy","year":"2017","journal-title":"J Card Fail"},{"key":"10.1016\/j.mcna.2025.04.003_bib7","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mcna.2025.04.003_bib8","series-title":"Sacubitril\/valsartan [package insert]","year":"2024"},{"issue":"11","key":"10.1016\/j.mcna.2025.04.003_bib9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.mcna.2025.04.003_bib10","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1161\/CIRCULATIONAHA.118.039331","article-title":"Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril\/valsartan or enalapril in the PIONEER-HF trial","volume":"139","author":"Morrow","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.mcna.2025.04.003_bib11","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilized heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Failure"},{"issue":"23","key":"10.1016\/j.mcna.2025.04.003_bib12","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure, results of the cooperative north Scandinavian enalapril survival study","volume":"316","author":"Swedbery","year":"1987","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.003_bib13","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.mcna.2025.04.003_bib14","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chromic heart failure ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"9386","key":"10.1016\/j.mcna.2025.04.003_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"issue":"9215","key":"10.1016\/j.mcna.2025.04.003_bib16","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2025.04.003_bib17","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2025.04.003_bib18","series-title":"Metoprolol succinate [package insert]","year":"2023"},{"key":"10.1016\/j.mcna.2025.04.003_bib19","series-title":"Bisoprolol fumarate [package insert]","year":"2024"},{"key":"10.1016\/j.mcna.2025.04.003_bib20","series-title":"Carvedilol","year":"2023"},{"issue":"20","key":"10.1016\/j.mcna.2025.04.003_bib21","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1016\/j.jacc.2017.03.563","article-title":"Achieving a maximally tolerated b-blocker dose in heart failure patients. Is there room for improvement?","volume":"69","author":"Bhatt","year":"2017","journal-title":"JACC (J Am Coll Cardiol)"},{"issue":"9146","key":"10.1016\/j.mcna.2025.04.003_bib22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomized trial","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"9169","key":"10.1016\/j.mcna.2025.04.003_bib23","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/CL in chronic heart failure: metoprolol CR\/XL randomized intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"9377","key":"10.1016\/j.mcna.2025.04.003_bib24","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European Trial (COMET): randomized controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2025.04.003_bib25","series-title":"Spironolactone [package insert]","year":"1960"},{"key":"10.1016\/j.mcna.2025.04.003_bib26","series-title":"Eplerenone [package insert]","year":"2002"},{"issue":"10","key":"10.1016\/j.mcna.2025.04.003_bib27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.mcna.2025.04.003_bib28","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.003_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.04.003_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.36628\/ijhf.2022.0030","article-title":"SGLT-2 inhibitors in heart failure: a review of current evidence","volume":"5","author":"Talha","year":"2023","journal-title":"Int J Heart Fail"},{"issue":"22","key":"10.1016\/j.mcna.2025.04.003_bib31","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.mcna.2025.04.003_bib32","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.mcna.2025.04.003_bib33","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mcna.2025.04.003_bib34","series-title":"Dapagliflozin [package insert]","year":"2023"},{"key":"10.1016\/j.mcna.2025.04.003_bib35","series-title":"Empagliflozin [package insert]","year":"2023"},{"issue":"5","key":"10.1016\/j.mcna.2025.04.003_bib36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJM199108013250502","article-title":"A comparison of enalapril with hydralazine\u2013isosorbide dinitrate in the treatment of chronic congestive heart failure","volume":"325","author":"Cohn","year":"1991","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.mcna.2025.04.003_bib37","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor","year":"2004","journal-title":"N Eng J Med"},{"key":"10.1016\/j.mcna.2025.04.003_bib38","series-title":"Digoxin [package insert]","year":"2015"},{"key":"10.1016\/j.mcna.2025.04.003_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2025.04.003_bib40","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/ehi687","article-title":"Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.mcna.2025.04.003_bib41","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jacc.2017.12.060","article-title":"Digoxin and mortality in patients with atrial fibrillation","volume":"71","author":"Lopes","year":"2018","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.mcna.2025.04.003_bib42","series-title":"Ivabradine [package insert]","year":"2019"},{"key":"10.1016\/j.mcna.2025.04.003_bib43","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"On behalf of the SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2025.04.003_bib44","series-title":"Vericiguat [package insert]","year":"2021"},{"key":"10.1016\/j.mcna.2025.04.003_bib45","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mcna.2025.04.003_bib46","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2025.04.003_bib47","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.mcna.2025.04.003_bib48","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.mcna.2025.04.003_bib49","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.mcna.2025.04.003_bib50","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.003_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.mcna.2025.04.003_bib52","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.mcna.2025.04.003_bib53","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.jacc.2023.03.393","article-title":"2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction","volume":"81","author":"Kittleson","year":"2023","journal-title":"JACC (J Am Coll Cardiol)"},{"key":"10.1016\/j.mcna.2025.04.003_bib54","series-title":"Furosemide [package insert]","year":"2010"},{"issue":"6","key":"10.1016\/j.mcna.2025.04.003_bib55","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJM199808063390607","article-title":"Diuretic therapy","volume":"339","author":"Brater","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.mcna.2025.04.003_bib56","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/jama.2022.23924","article-title":"Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: the TRANSFORM-HF randomized clinical trial","volume":"329","author":"Mentz","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2025.04.003_bib57","series-title":"FUROSCIX [package insert]","year":"2024"},{"key":"10.1016\/j.mcna.2025.04.003_bib58","first-page":"1830","article-title":"Avoiding treatment in hospital with subcutaneous furosemide for worsening heart failure: a pilot study (AT HOME-HF)","volume":"11","author":"Konstam","year":"2024","journal-title":"J Am Coll Cardiol HF"},{"key":"10.1016\/j.mcna.2025.04.003_bib59","series-title":"Dobutamine [package insert]","year":"2016"},{"key":"10.1016\/j.mcna.2025.04.003_bib60","series-title":"Milrinone [package insert]","year":"2021"},{"key":"10.1016\/j.mcna.2025.04.003_bib61","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and iron deficiency in heart failure","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.003_bib62","first-page":"36","article-title":"Iron deficiency in heart failure: an overview","volume":"7","author":"Haehling","year":"2019","journal-title":"J Am Coll Cardiol HF"},{"issue":"36","key":"10.1016\/j.mcna.2025.04.003_bib63","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1093\/eurheartj\/ehu235","article-title":"Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at highest risk of death after an episode of heart failure","volume":"35","author":"Jankowska","year":"2014","journal-title":"Eu Heart J"},{"issue":"1","key":"10.1016\/j.mcna.2025.04.003_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2020.10.014","article-title":"Treatment of HF in an era of multiple therapies","volume":"9","author":"Bhatt","year":"2021","journal-title":"JACC Heart Failure"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:03:29Z","timestamp":1761181409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712525000604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":64,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0025712525000604"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2025.04.003","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heart Failure Pharmacotherapy","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2025.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}